Riding Outsourcing Wave, Ex-Teva Exec To Head CRO Albany Molecular
This article was originally published in The Pink Sheet Daily
Executive Summary
A year after leaving Teva as a full-time employee, Bill Marth will succeed Albany Molecular Research’s founding CEO at the beginning of 2014. The company believes an increase in capital availability and a return to R&D spending will fuel a trend toward outsourced pharma services.